Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (CSTL) delivers innovative diagnostic solutions that transform cancer care through genomic insights. This news hub provides investors and healthcare professionals with essential updates on the company’s advancements in precision oncology diagnostics.
Access authoritative information about CSTL’s latest developments, including new test validations, clinical study results, and strategic partnerships. Our curated collection features earnings reports, regulatory milestones, and research breakthroughs across key focus areas like melanoma diagnostics and pharmacogenomics.
Stay informed about critical updates including:
- FDA-cleared test announcements
- Peer-reviewed study publications
- Financial performance reports
- Collaborative oncology initiatives
- Expanded clinical utility data
Bookmark this page for streamlined access to Castle Biosciences’ verified news. Check regularly for updates that impact diagnostic practices and investment considerations in the genomic testing sector.
Castle Biosciences (NASDAQ: CSTL) has presented new data at the 19th European Association of Dermato-Oncology Congress in Rome, highlighting the effectiveness of its DecisionDx®-Melanoma test for patients with stage I cutaneous melanoma (CM). This innovative test enhances risk stratification compared to the traditional AJCC staging, which relies solely on clinical and pathologic factors. Specifically, DecisionDx-Melanoma shows improved recurrence-free survival (RFS) rates of 97.3% for low-risk Class 1A compared to 77.3% for high-risk Class 2B. Additionally, it demonstrates better melanoma-specific survival (MSS) with rates of 98.0% for Class 1A versus 92.3% for Class 2B. Notably, high-risk patients identified by the test were 5.4 times more likely to die from melanoma compared to AJCC-staged patients, indicating the potential of DecisionDx-Melanoma in guiding enhanced clinical care.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced new findings from a patient simulation study to be presented at ESGE Days 2023. The study indicated that the TissueCypher® Barrett’s Esophagus test significantly enhances management decisions for patients with low-grade dysplasia (LGD) in Barrett’s esophagus (BE). Results showed that the likelihood of appropriate treatment increased from 9% with pathology alone to 77.3% when using TissueCypher results. This test may help reduce both unnecessary endoscopies for low-risk patients and improve outcomes for high-risk patients. The presentation will occur on April 22 in Dublin, Ireland, highlighting the potential of TissueCypher to standardize treatment and reduce the risk of advancing to esophageal cancer.
Castle Biosciences, Inc. (NASDAQ: CSTL) will release its financial results for the first quarter ended March 31, 2023, on May 3, 2023, after market close. Management will conduct a conference call and webcast at 4:30 p.m. Eastern Time to discuss these results. Interested parties can access the live webcast through the Company's Investor Relations page, with a replay available afterward. Castle Biosciences provides innovative tests for skin cancers, uveal melanoma, Barrett’s esophagus, and mental health conditions, and is progressing with R&D for other high-need diseases, including therapies for psoriasis and atopic dermatitis.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
